• Maintain a Compliant 340B Program in Your Hospital

    Through RxStrategies’ hospital-focused services, hospitals can manage and track grant funded subsidies, manage 340B product purchases and inventory, participate in P&T committees, manage pharmacies, receive consulting services to improve financial, operational and strategic management and more. The comprehensive solutions that allow hospitals to maintain a compliant 340B program include: Split Billing – Addresses the complexity… Read more »

  • December 2017 – 340B Insider

      Welcome to the December edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. 340B HEALTH URGES ACTION: Stop 340B Hospital Cuts The time is now to contact your Senators and Representatives regarding H.R. 4392 to stop the $1.6 billion in cuts effective Jan. 1, 2018. RxStrategies… Read more »

  • Clinical Insights: December 12, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lonhala™ Magnair™ (glycopyrrolate) – December 5, 2017 – Sunovion Pharmaceuticals Inc. (Sunovion) announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application… Read more »

  • Ensure and Maximize 340B Program Compliance

    We assist retail and specialty pharmacies in ensuring 340B program security, efficiency and safety. With this solution, you will be able to maximize compliance, visibility, capture rate, inventory reconciliation and more.   Key Elements of Our Enterprise Backbone for Retail and Specialty Pharmacies • Serves as data clearinghouse for all your contracted TPAs (Third Party… Read more »

  • Clinical Insights: November 13, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] – New Vaccine Approval – November 9, 2017 – Dynavax Technologies Corporation announced that the U.S. Food and Drug Administration… Read more »

  • November 2017 – 340B Insider

    Welcome to the November edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. 340B INDUSTRY NEWS CMS UPDATE: Final Regulation Cuts Nearly 30 Percent in Medicare Part B Drug Payments to 340B Hospitals As you are aware, Centers for Medicare & Medicaid Services (CMS) published on 11/1/17,… Read more »

  • Clinical Insights: October 24, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Shingrix (Zoster Vaccine Recombinant, Adjuvanted) – New Vaccine Approval – October 20, 2017 – GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has… Read more »

  • October 2017 – 340B Insider

    Welcome to the October edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.    340B INDUSTRY NEWS UPDATE: HOUSE ENERGY & COMMERCE OVERSIGHT SUBCOMMITTEE HEARING On October 11, the House Energy & Commerce (E&C) oversight subcommittee held a second hearing on the 340B program, focusing on how Covered… Read more »

  • Clinical Insights: October 16, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Formulation Approval Lyrica® CR (pregabalin) – October 12, 2017 – Pfizer Inc. announced that the United States Food and Drug Administration… Read more »